<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24948110</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-0142</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>120</Volume>
            <Issue>22</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Nov</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer</Title>
          <ISOAbbreviation>Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The MAPK pathway across different malignancies: a new perspective.</ArticleTitle>
        <Pagination>
          <StartPage>3446</StartPage>
          <EndPage>3456</EndPage>
          <MedlinePgn>3446-56</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28864</ELocationID>
        <Abstract>
          <AbstractText>The mitogen-activated protein kinase/extracellular signal-regulated (MAPK/ERK) pathway is activated by upstream genomic events and/or activation of multiple signaling events in which information coalesces at this important nodal pathway point. This pathway is tightly regulated under normal conditions by phosphatases and bidirectional communication with other pathways, like the protein kinase B/mammalian target of rapamycin (AKT/m-TOR) pathway. Recent evidence indicates that the MAPK/ERK signaling node can function as a tumor suppressor as well as the more common pro-oncogenic signal. The effect that predominates depends on the intensity of the signal and the context or tissue in which the signal is aberrantly activated. Genomic profiling of tumors has revealed common mutations in MAPK/ERK pathway components, such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF). Currently approved for the treatment of melanoma, inhibitors of BRAF kinase are being studied alone and in combination with inhibitors of the MAPK and other pathways to optimize the treatment of many tumor types. Therapies targeted toward MAPK/ERK components have various response rates when used in different solid tumors, such as colorectal cancer and ovarian cancer. Understanding the differential nature of activation of the MAPK/ERK pathway in each tumor type is critical in developing single and combination regimens, because different tumors have unique mechanisms of primary and secondary signaling and subsequent sensitivity to drugs.</AbstractText>
          <CopyrightInformation>© 2014 American Cancer Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Burotto</LastName>
            <ForeName>Mauricio</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chiou</LastName>
            <ForeName>Victoria L</ForeName>
            <Initials>VL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Jung-Min</ForeName>
            <Initials>JM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kohn</LastName>
            <ForeName>Elise C</ForeName>
            <Initials>EC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>Z99 CA999999</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>06</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer</MedlineTA>
        <NlmUniqueID>0374236</NlmUniqueID>
        <ISSNLinking>0008-543X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.12.2</RegistryNumber>
          <NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020929" MajorTopicYN="N">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">extracellular signal-regulated kinase (ERK)</Keyword>
        <Keyword MajorTopicYN="N">melanoma</Keyword>
        <Keyword MajorTopicYN="N">mitogen-activated protein kinase (MAPK)</Keyword>
        <Keyword MajorTopicYN="N">mitogen-activated protein kinase-kinase (MEK)</Keyword>
        <Keyword MajorTopicYN="N">ovarian cancer</Keyword>
        <Keyword MajorTopicYN="N">signaling</Keyword>
        <Keyword MajorTopicYN="N">v-raf murine sarcoma viral oncogene homolog (BRAF)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>6</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>6</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24948110</ArticleId>
        <ArticleId IdType="mid">NIHMS602765</ArticleId>
        <ArticleId IdType="pmc">PMC4221543</ArticleId>
        <ArticleId IdType="doi">10.1002/cncr.28864</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hudson TJ, Anderson W, Artez A, et al.  International network of cancer genome projects. Nature. 2010;464(7291):993–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2902243</ArticleId>
            <ArticleId IdType="pubmed">20393554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4320046</ArticleId>
            <ArticleId IdType="pubmed">24071851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077–80. discussion 80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18451130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl 2):S17–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22443084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang SH, Sharrocks AD, Whitmarsh AJ. MAP kinase signalling cascades and transcriptional regulation. Gene. 2013;513(1):1–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23123731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3749880</ArticleId>
            <ArticleId IdType="pubmed">23539594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13(9):663–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23949426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12778136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muram-Zborovski TM, Stevenson DA, Viskochil DH, Dries DC, Wilson AR, Rong M. SPRED 1 mutations in a neurofibromatosis clinic. J Child Neurol. 2010;25(10):1203–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3243064</ArticleId>
            <ArticleId IdType="pubmed">20179001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan PT, Garnett MJ, Roe SM, et al.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15035987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal. 2004;16(7):769–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15115656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cossa G, Gatti L, Cassinelli G, Lanzi C, Zaffaroni N, Perego P. Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Curr Pharm Des. 2013;19(5):883–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22973957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhanasekaran N, Premkumar Reddy E. Signaling by dual specificity kinases. Oncogene. 1998;17(11 Reviews):1447–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9779990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997;9(2):180–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9069255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pullikuth AK, Catling AD. Scaffold mediated regulation of MAPK signaling and cytoskeletal dynamics: a perspective. Cell Signal. 2007;19(8):1621–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2233890</ArticleId>
            <ArticleId IdType="pubmed">17553668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121(2):179–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15851026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu B, Soncin F, Price BD, Stevenson MA, Calderwood SK. Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1. J Biol Chem. 1996;271(48):30847–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8940068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmid RS, Pruitt WM, Maness PF. A MAP kinase-signaling pathway mediates neurite outgrowth on L1 and requires Src-dependent endocytosis. J Neurosci. 2000;20(11):4177–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6772629</ArticleId>
            <ArticleId IdType="pubmed">10818153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf I, Rubinfeld H, Yoon S, Marmor G, Hanoch T, Seger R. Involvement of the activation loop of ERK in the detachment from cytosolic anchoring. J Biol Chem. 2001;276(27):24490–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11328824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zassadowski F, Rochette-Egly C, Chomienne C, Cassinat B. Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. Cell Signal. 2012;24(12):2369–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22906493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigoillot FD, Evans DR, Guy HI. Growth-dependent regulation of mammalian pyrimidine biosynthesis by the protein kinase A and MAPK signaling cascades. J Biol Chem. 2002;277(18):15745–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11872754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13(9):679–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23954936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winters ME, Mehta AI, Petricoin EF, 3rd, Kohn EC, Liotta LA. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. Cancer Res. 2005;65(9):3853–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15867384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol. 2002;4(8):556–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12134156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy T, Hori S, Sewell J, Gnanapragasam VJ. Expression and functional role of negative signalling regulators in tumour development and progression. Int J Cancer. 2010;127(11):2491–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20607827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 2007;1773(8):1161–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758354</ArticleId>
            <ArticleId IdType="pubmed">17306385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, et al.  Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev. 2013;27(8):900–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3650227</ArticleId>
            <ArticleId IdType="pubmed">23599344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593–602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9054499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bric A, Miething C, Bialucha CU, et al.  Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell. 2009;16(4):324–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2829755</ArticleId>
            <ArticleId IdType="pubmed">19800577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17496923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5224525</ArticleId>
            <ArticleId IdType="pubmed">24048068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3178447</ArticleId>
            <ArticleId IdType="pubmed">20179705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solit DB, Garraway LA, Pratilas CA, et al.  BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3306236</ArticleId>
            <ArticleId IdType="pubmed">16273091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bollag G, Hirth P, Tsai J, et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2948082</ArticleId>
            <ArticleId IdType="pubmed">20823850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boni A, Cogdill AP, Dang P, et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70(13):5213–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20551059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bekaii-Saab T, Phelps MA, Li X, et al.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3107751</ArticleId>
            <ArticleId IdType="pubmed">21519026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho AL, Grewal RK, Leboeuf R, et al.  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3615415</ArticleId>
            <ArticleId IdType="pubmed">23406027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janne PA, Shaw AT, Pereira JR, et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14(1):38–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23200175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sosman JA, Kim KB, Schuchter L, et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3724515</ArticleId>
            <ArticleId IdType="pubmed">22356324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hauschild A, Grob JJ, Demidov LV, et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22735384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vin H, Ching G, Ojeda SS, et al.  Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK. Mol Cancer Ther. 2014;13(1):221–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4366425</ArticleId>
            <ArticleId IdType="pubmed">24170769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flaherty KT, Infante JR, Daud A, et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549295</ArticleId>
            <ArticleId IdType="pubmed">23020132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. Food and Drug Administration: Trametinib and Dabrafenib approbal. 2014. </Citation>
        </Reference>
        <Reference>
          <Citation>Thomas RK, Baker AC, Debiasi RM, et al.  High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39(3):347–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17293865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lynch TJ, Bell DW, Sordella R, et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15118073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pao W, Miller VA, Politi KA, et al.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC549606</ArticleId>
            <ArticleId IdType="pubmed">15737014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paraiso KH, Xiang Y, Rebecca VW, et al.  PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3070772</ArticleId>
            <ArticleId IdType="pubmed">21317224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res. 2009;15(3):752–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2676228</ArticleId>
            <ArticleId IdType="pubmed">19188143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011;82(3):201–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4001781</ArticleId>
            <ArticleId IdType="pubmed">21635872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Daouti S, Li WH, et al.  Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the BRafV600E mutation. Cancer Res. 2011;71(16):5535–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21705440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montagut C, Sharma SV, Shioda T, et al.  Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;68(12):4853–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2692356</ArticleId>
            <ArticleId IdType="pubmed">18559533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roskoski R., Jr RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun. 2010;399(3):313–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20674547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poulikakos PI, Persaud Y, Janakiraman M, et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature. 2011;480(7377):387–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3266695</ArticleId>
            <ArticleId IdType="pubmed">22113612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010;3(149):ra84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3372405</ArticleId>
            <ArticleId IdType="pubmed">21098728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382(9893):720–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23972815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013;73(15):4840–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3748389</ArticleId>
            <ArticleId IdType="pubmed">23737487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romano E, Pradervand S, Paillusson A, et al.  Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. Clin Cancer Res. 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23948972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4521623</ArticleId>
            <ArticleId IdType="pubmed">24048065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Nicolantonio F, Martini M, Molinari F, et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19001320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richman SD, Seymour MT, Chambers P, et al.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27(35):5931–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19884549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prahallad A, Sun C, Huang S, et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22281684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao M, Tian F, Mariadason JM, et al.  Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19(3):657–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3563727</ArticleId>
            <ArticleId IdType="pubmed">23251002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spreafico A, Tentler JJ, Pitts TM, et al.  Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013;19(15):4149–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3905307</ArticleId>
            <ArticleId IdType="pubmed">23757356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohn EC, Romano S, Lee JM. Clinical implications of using molecular diagnostics for ovarian cancers. Ann Oncol. 2013;24(Suppl 10):x22–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3836571</ArticleId>
            <ArticleId IdType="pubmed">24265398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25(1):32–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3868320</ArticleId>
            <ArticleId IdType="pubmed">24225019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1615664</ArticleId>
            <ArticleId IdType="pubmed">15111296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18(Suppl 2):S19–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15761464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer G, Oldt R, 3rd, Cohen Y, et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12644542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grisham RN, Iyer G, Garg K, et al.  BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013;119(3):548–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3961140</ArticleId>
            <ArticleId IdType="pubmed">22930283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64(19):6915–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15466181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farley J, Brady WE, Vathipadiekal V, et al.  Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3627419</ArticleId>
            <ArticleId IdType="pubmed">23261356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matei D, Sill MW, Lankes HA, et al.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2011;29(1):69–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3055861</ArticleId>
            <ArticleId IdType="pubmed">21098323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou JY, Rodriguez-Gabin A, Samaweera L, et al.  Exploiting MEK inhibitor-mediated activation of ERalpha for therapeutic intervention in ER-positive ovarian carcinoma. PLoS One. 2013;8(2):e54103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3563537</ArticleId>
            <ArticleId IdType="pubmed">23390495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colombino M, Capone M, Lissia A, et al.  BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30(20):2522–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22614978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edlundh-Rose E, Egyhazi S, Omholt K, et al.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006;16(6):471–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17119447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies H, Bignell GR, Cox C, et al.  Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12068308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murugan AK, Dong J, Xie J, Xing M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle. 2009;8(13):2122–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19411838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikolaev SI, Rimoldi D, Iseli C, et al.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 2012;44(2):133–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22197931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seo JS, Ju YS, Lee WC, et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22(11):2109–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3483540</ArticleId>
            <ArticleId IdType="pubmed">22975805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardarella S, Ogino A, Nishino M, et al.  Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19(16):4532–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3762878</ArticleId>
            <ArticleId IdType="pubmed">23833300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3401966</ArticleId>
            <ArticleId IdType="pubmed">22810696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361(1):98–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19571295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sieben NL, Macropoulos P, Roemen GM, et al.  In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol. 2004;202(3):336–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14991899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bansal M, Gandhi M, Ferris RL, et al.  Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am J Surg Pathol. 2013;37(10):1586–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23797723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing M, Alzahrani AS, Carson KA, et al.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3791140</ArticleId>
            <ArticleId IdType="pubmed">23571588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen Y, Xing M, Mambo E, et al.  BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95(8):625–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12697856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xi L, Arons E, Navarro W, et al.  Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(14):3330–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3321859</ArticleId>
            <ArticleId IdType="pubmed">22210875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tiacci E, Trifonov V, Schiavoni G, et al.  BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3689585</ArticleId>
            <ArticleId IdType="pubmed">21663470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turke AB, Zejnullahu K, Wu YL, et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17(1):77–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2980857</ArticleId>
            <ArticleId IdType="pubmed">20129249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng KP, Hillmer AM, Chuah CT, et al.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18(4):521–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22426421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakagawa T, Takeuchi S, Yamada T, et al.  EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 2013;73(8):2428–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23382048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi S, Boggon TJ, Dayaram T, et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15728811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sequist LV, Waltman BA, Dias-Santagata D, et al.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3132801</ArticleId>
            <ArticleId IdType="pubmed">21430269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takezawa K, Pirazzoli V, Arcila ME, et al.  HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2(10):922–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3473100</ArticleId>
            <ArticleId IdType="pubmed">22956644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman JA, Zejnullahu K, Mitsudomi T, et al.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17463250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whittaker SR, Theurillat JP, Van Allen E, et al.  A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013;3(3):350–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3606893</ArticleId>
            <ArticleId IdType="pubmed">23288408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maertens O, Johnson B, Hollstein P, et al.  Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013;3(3):338–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3595355</ArticleId>
            <ArticleId IdType="pubmed">23171796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atefi M, von Euw E, Attar N, et al.  Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011;6(12):e28973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3237573</ArticleId>
            <ArticleId IdType="pubmed">22194965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corcoran RB, Ebi H, Turke AB, et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3308191</ArticleId>
            <ArticleId IdType="pubmed">22448344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheppard KE, Cullinane C, Hannan KM, et al.  Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer. 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24011934</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
